Thalidomide Treatment Reduces Tumor Necrosis Factor α Production and Enhances Weight Gain in Patients with Pulmonary Tuberculosis

Table 3 White blood cell counts and differentials

		Cell Count per mm³ of Blood (mean ± SD)
		Total WBCs	Lymphocyte	Monocyte	Eosinophil
Thalidomide
HIV⁺	pre	6765 ± 2286	1700 ± 927	359 ± 276	318 ± 247
	mid	6403 ± 2489	1438 ± 669	320 ± 237	463 ± 562
	post	6331 ± 1564	1784 ± 1165	427 ± 273	703 ± 562
HIV⁻	pre	8435 ± 3519	1762 ± 876	579 ± 367	513 ± 492
	mid	7560 ± 2402	2402 ± 1294	393 ± 301	524 ± 613
	post	6941 ± 1735	2310 ± 801	454 ± 393	445 ± 451
Placebo
HIV⁺/1⁻	pre	7573 ± 3289	1699 ± 440	616 ± 392	195 ± 151
	mid	6806 ± 3035	2140 ± 1019	336 ± 198	317 ± 321
	post	6588 ± 4012	2024 ± 806	282 ± 170	178 ± 167

Results are means ± one standard deviation (SD) evaluated before (pre), during (mid), and 5 days after (post) 14-day treatment cycles with 300 mg/day of thalidomide or placebo (see Table 1). No significant changes were observed. WBC, white blood cells.

ISSN: 1528-3658